Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed and dated a consent form agreeing to take part in the study
• People aged 18 to 75 years old
• People who have been confirmed through tissue or cell testing to have pancreatic adenocarcinoma (a specific type of pancreatic cancer)
• People who have had surgery to remove their cancer, with pathology results showing the tumour was fully or mostly removed (called R0 or R1 resection)
• People who have not received any treatment for their cancer before surgery (no neoadjuvant therapy)
• People with a performance score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in daily activity
• People whose doctors estimate they have a life expectancy of more than 12 months
• People whose CA19-9 blood marker level was below 100 U/mL before starting chemotherapy (CA19-9 is a protein sometimes associated with pancreatic cancer)
• People whose liver, kidneys, and bone marrow are functioning well enough, as confirmed by blood tests required by the study
• Women who could become pregnant must have a negative pregnancy test and must follow the contraception guidelines set out in the study protocol

Who may not be able to join:

• People whose pancreatic cancer was classified as "borderline resectable" (meaning it was on the border of being operable)
• People who have any signs of the cancer coming back or spreading to other parts of the body after surgery
• People who have fluid in the abdomen caused by cancer (malignant ascites)
• People who have inflammatory bowel disease, a bowel blockage (full or partial), or ongoing severe diarrhoea after surgery
• People who need long-term medication to manage allergies, or who are known to be allergic to any ingredient in the study treatment
• People with a history of autoimmune disease (conditions where the immune system attacks the body's own tissues)
• People who have had a stroke, mini-stroke (TIA), or brain bleed within the 6 months before the screening visit
• People who have had a heart attack within the 6 months before screening, or who have uncontrolled chest pain, uncontrolled irregular heartbeat, or serious heart failure (NYHA Class III or higher)
• People who received certain immune-boosting medications (such as IL-2, CTLA-4 inhibitors, CD40 agonists, CD137 agonists, or IFN-α) within 4 weeks before the first dose of the study drug
• People who received a blood transfusion or certain blood-stimulating injections (EPO, G-CSF, or GM-CSF) within 7 days before the first dose of the study drug
• People who have previously received a therapeutic cancer vaccine
• People who have an immune deficiency condition, whether present from birth or developed later in life
• People who are currently enrolled in another clinical trial and have not withdrawn before screening
• People who, in the investigator's judgement, may be unable or unwilling to follow the study requirements due to health, mental health, or personal circumstances
• People who, in the investigator's opinion, have any other condition that would make joining the trial inappropriate

Important: Always verify eligibility with the trial site directly before applying.